Karin Brown
Pfizer (United States)(US)
Publications by Year
Research Areas
Chemical Synthesis and Analysis, Alzheimer's disease research and treatments, Protein Kinase Regulation and GTPase Signaling, Acute Myeloid Leukemia Research, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer(2020)572 cited
- → Discovery of 7-Tetrahydropyran-2-yl Chromans: β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors That Reduce Amyloid β-Protein (Aβ) in the Central Nervous System(2014)38 cited
- → 8-Tetrahydropyran-2-yl Chromans: Highly Selective Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors(2014)18 cited
- → Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM)(2012)11 cited
- → Discovery of Potent and Selective Covalent Inhibitors of HER2WT and HER2YVMA(2024)4 cited
- → Design of Potent Menin–KMT2A Interaction Inhibitors with Improved In Vitro ADME Properties and Reduced hERG Affinity(2024)3 cited
- → Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer(2024)3 cited
- → Novel O-methylpyrimidine prodrugs of phenolic compounds bioactivated by aldehyde oxidase: Enhancing metabolic stability against first-pass conjugative metabolism in the intestine(2025)1 cited
- → Application of MetMax™ pooled donor human hepatocytes in a higher throughput assay for human hepatic metabolic stability screening(2018)